Drug Profile
RXC 004
Alternative Names: Porcupine inhibitor - Redx Pharma; RXC-004Latest Information Update: 22 Jan 2024
Price :
$50
*
At a glance
- Originator Redx Pharma
- Class Antifibrotics; Antineoplastics; Small molecules
- Mechanism of Action PORCN protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Biliary cancer; Colorectal cancer; Pancreatic cancer
- Phase I/II Solid tumours
- No development reported Fibrosis
Most Recent Events
- 30 Nov 2023 Redx Pharma in collaboration with Merck & Co completes a phase II PORCUPINE2/KEYNOTE-E86 trial in Biliary cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in United Kingdom, Australia (PO) (NCT04907851)
- 30 Nov 2023 Redx Pharma in collaboration with Merck & Co completes a phase II PORCUPINE2/KEYNOTE-E86 trial in Biliary cancer (Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in United Kingdom, Australia (PO) (NCT04907851)
- 30 Nov 2023 Redx Pharma in collaboration with Merck & Co completes a phase II PORCUPINE2/KEYNOTE-E86 trial in Pancreatic cancer (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in United Kingdom, Australia (PO) (NCT04907851)